Abstract:Abstract Abstract 4621 Objective: Canonical Wnt signaling controls embryonic development, regulates cell growth, transference and differentiation, it also involves in the self-renewal process of normal tissue and multiplication of stem cell. Recently, the aberrant activation of the Wnt signaling pathway has been implicated in the pathogenesis of human neoplasm including leukemia. LEF1, as a major transcriptional factor of Wnt signaling, plays a pivotal role in lymphoid differentiation as well as in granulopoiesis. High expression of LEF1 has been proposed to be a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia (AML). In this study, we firstly investigated the expression level of LEF1 mRNA and its clinical significance in Chinese AML. Methods: 87 samples from 81 Chinese AML patients (81 primary untreated samples and 6 samples after induction therapy) and 14 healthy controls were collected in this study. The LEF1 mRNA expressions were measured by real-time PCR with fluorescent dye SYBR Green I, the GAPDH was used as internal control. The relative quantitative value of LEF1 expression was calculated by means of 2 (−ΔCt). We analyzed the results with established AML prognostic factors such as karyotype, gene mutations, fusion proteins, relapse-free survival (RFS) and overall survival (OS). Results: The expression level of LEF1 mRNA in 81 AML patients was significantly higher than 14 normal controls (p <0.001). LEF1 expression level was further analyzed in the subgroups distinguished by clinical characters. According to national comprehension cancer network (NCCN) guideline, we found that LEF1 was dramatically increased in patients with better risk karyotype group (n=18) than those with the intermediate risk karyotype group (n=51) (P=0.031); patients with PML-RARα positive (n=16) and AML1-ETO positive (n=5) have higher LEF1 level compared with those without PML-RARα or AML1-ETO (n=60). Among 70 patients who have received the induction therapy, we discovered that patients with relative higher LEF1 expression were more likely to achieve CR after first induction therapy (p= 0.031; CR: n=44, no CR: n=26); we further analyzed the samples before and after treatment from 6 patients who achieved CR, the results showed that the LEF1 level were dramatically decreased after first induction therapy (p=0.028). We can not find the differences in RFS and OS between low LEF1 expression group and high LEF1 expression group in total patients. However, among the AML patients with intermediate risk cytogenetic, the lower LEF1 expression was associated with worse RFS (median, 15.0 vs 31.7 months, P=0.044) and OS (median, 16.7 vs 33.7 months, P=0.046) compared with the higher LEF1 expression. Conclusion: These results showed the LEF1 expression in AML patients is markedly higher than normal controls, especially in patients with favorable risk karyotype and PML-RARα or AML1-ETO positive. Patients with higher LEF1 expression seems to more likely to achieve CR after induction therapy. Survival analysis revealed that the higher LEF1 expression patients have a significantly prolonged RFS and OS compared to the lower LEF1 expression patients in intermediate risk karyotype group of AML. Our results in Chinese patients verified that LEF1 can be a potential favorable marker in AML patients. Disclosures: No relevant conflicts of interest to declare.

Elevated Nuclear Phospho-Eif4e Body Levels Are Associated with Tumor Progression and Poor Prognosis for Acute Myeloid Leukemia

Phospho-eIF4E: a New Target for Acute Myeloid Leukemia.

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

Translational Regulator Eif2α in Tumor

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.

Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression]

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

High Expression of EBP is an Adverse Prognostic Factor for De Novo Acute Myeloid Leukemia

Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells

High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer

Abstract 272: Novel role for eIF4E in homing of acute myeloid leukemia cells

eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia

Tumor Microenvironmental Competitive Endogenous RNA Network and Immune Cells Act As Robust Prognostic Predictor of Acute Myeloid Leukemia

The Eef1a Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies

Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers

N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia

Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia

The Expression of LEF1 Gene and Its Clinical Significance in Chinese Patients with Acute Myeloid Leukemia

RNA N6-methyladenosine Reader IGF2BP3 Promotes Acute Myeloid Leukemia Progression by Controlling Stabilization of EPOR Mrna.